HYPERTENSION EFFECTS ON THE DECREASED KIDNEY FUNCTION PROGRESIVITY IN BENIGN PROSTATIC HYPERPLASIA PATIENTS
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
Objective: A comprehensive knowledge about BPH and hypertension is needed to reduce morbidity and mortality in patients with decreased kidney function due to the two diseases. Material & Methods: This research used the observational analytics method with cross-sectional design. This research used secondary data from medical records of BPH patients in Bina Sehat Hospital and Paru Hospital from January 1st to December 1st 2019. Results: Comparative serum creatinine test results in hypertensive BPH patients with non-hypertensive BPH patients using the Mann Whitney test, obtained p= 0.000. Based on these results it can be concluded that there are significant differences in serum creatinine between hypertensive BPH patients and non-hypertensive BPH patients. Correlation test results using the Spearman test between serum creatinine with blood pressure systole and diastole all samples obtained each p= 0.000 r= 0.399 for systolic blood pressure and p= 0.000 r= 0.337 for diastole blood pressure. Based on these results it can be concluded that there is a significant correlation between serum creatinine with systolic and diastolic blood pressure of the patient. Conclusion: Hypertension will worsen the kidney function decline in BPH patients seen from an increase in serum creatinine.
##plugins.themes.bootstrap3.article.details##
BPH, hypertension, kidney function, creatinine, blood pressure
Robert, G., Descazeaud A., Nicolaiew, N., Terry, S., Sirab, N., Vacherot, F., Maille, P., Allory, Y., de la Taille, A. Inflammation in benign prostatic hyperplasia: a 282 patient’s immunohistochemical analysis. The Prostate. 2009; 69(16): 1774-1780.
Kocjancic, E. Benign Prostatic Hyperplasia (BPH). Encyclopedia of Reproduction. 2018; 4(2): 467-72.
Lee, S. H., Park, K. K., Mah, S. Y., Chung, B. H. Effect of alfa-blocker ‘add on’ treatment on blood pressure in symptomatic BPH with or without concominant hypertension. Prostate Cancer and Prostatic Disease. 2010; 13(4): 333-337
Mathur, R. P., Nayak, S., Sivaramakrishnan, R., Jain, V. Role of Alpha Blockers in Hypertension with Benign Prostatic Hyperplasia. Journal of Association of Physicians of India. 2014; 62(9): 40-4.
Lim, K. B. Epidemiology of Clinical Benign Prostatic Hyperplasia. Asian Journal of Urology. 2017; 4(3): 148-151
Breyer, B. and Sarma, V. Hyperglycemia and Insulin Resistance and the Risk of BPH/LUTS: an Update on Recent Literature. Current Urology Report. 2014; 15(462): 1-6.
Kunz, R. et al. Meta Analysis: Effect of Monotherapy and Combination Therapy with Inhibitor of Renin Angiotensin System on Proteinuria in Renal Disease. Annals of Internal Medicine. 2008; 143: 30.
Kaplan, M.N. Kaplan’s Clinical Hypertension 10th Edition. Dallas: Lippincott Williams & Wilkins. 2010.
Coresh, J., Wei, L., McQuillan, G. Pravalence of High Blood Pressure and Elevated Serum Creatinine Level in the United States. Arch Intern Med. 2001. 161(9):1207-1216
Speakman, M. J., Cheng, X. Management of the Complication of BPH. Musgrove Park Hospital. 2014; 30(2): 208-213.
Buffet, L., Richetti, C. Chronic Kidney Disease and Hypertension: A Destructive Combination. US Pharmacist. 2012; 37(6): 26-29.
Cellek, S., Cameron, N. E., Cotter, M. A., Fry, C. H., Ilo, D. Microvascular Dysfunction and Efficacy of PDE5 Inhibitors in BPH-LUTS. National Reviews of Urology. 2014; 11: 231-241.
Tousoulis, D., Kampoli A. M., Stefanadis, C. The Role of Nitric Oxide on Endothelial Function. Current Vascular Pharmacology. 2012; 10: 4-18.
Peixoto, C. A., Gomes, F. O. The Role of Phosphodiesterase-5 inhibitors in Prostatic Inflammation: a Review. Journal of Inflammation. 2015; 12: 54.
Michel, M.C., Heerman, U., Schumacer, H., Mehlburger, L., Goepel, M. Association of Hypertension with Symptoms of Benign Prostatic Hyperplasia. The Journal of Urology. 2004; 172: 1390-1393.